Aspirin resistance: Focus on clinical endpoints

Gabriella Pusch, Gergely Feher, Katalin Kotai, Antal Tibold, Beata Gasztonyi, Andrea Feher, Elod Papp, Geza Lupkovics, Laszlo Szapary

Research output: Review article

21 Citations (Scopus)


INTRODUCTION: Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25%. However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. Nevertheless, the effectiveness of aspirin has been questioned by the emergence of the concept of aspirin resistance, which has been introduced as an explanation of the fact that a considerable proportion of patients treated with aspirin exhibit normal platelet function. OBJECTIVES AND METHODS: We systematically reviewed all available evidence till March 2008 on prevalence of aspirin resistance and its association with clinical outcome. We also collected articles showing the possible way of treatment. CONCLUSION: Analyzing the data of different laboratory methods aspirin resistance seems to be associated with poor clinical outcome, although currently no standardized or widely accepted definition of aspirin resistance exists. The widely used laboratory methods might not be comparable with each other; therefore, specific treatment recommendations for patients who exhibit high platelet reactivity during aspirin therapy or who have poor platelet inhibition by aspirin are not established.

Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalJournal of cardiovascular pharmacology
Issue number6
Publication statusPublished - dec. 1 2008


ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this